Cerecor Rebrands to Avalo Therapeutics. Eighteen months after completing its merger with Aevi Genomic Medicine, Cerecor is rebranding to Avalo Therapeutics. The rebranding to Avalo reflects the company’s aims to focus on three core indications, on immunology, immuno-oncology, and rare genetic diseases.
This two day live remote program is ideal for basic research and translational biology scientists who work with antibodies on a regular basis. This program which focuses on the types [….]
Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy ProgramsPublished on :
Patented high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology.
Mark Nardone is Director and Co-Founder of Bio-Trac®, a biotechnology training program that has served the scientific community for over 37 years, providing hands-on training workshops, designed by active researchers for research scientists, that focus on the latest relevant techniques that are necessary for laboratory research.
Neil Sheppard is an Immunologist educated in the UK at the Universities of Bristol and Oxford. He has over 18 years’ experience in the fields of vaccines and immunotherapies, including over a dozen years leading drug discovery and development programs in Big Pharma and Biotech.